Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

This study is a prospective, single-arm, multicenter study. The patients were given chemotherapy with nimotuzumab and sindilimab. To analyze the efficacy and safety of nimotuzumab combined with sindilizumab and chemotherapy in first-line treatment of advanced or recurrent or metastatic esophageal cancer.

Trial Details

NCT ID
NCT06718205
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Zhengzhou University
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Nimotuzumab
  • Sintilimab
  • Paclitaxel-albumin
  • Cisplatin
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • All of the following participants will be enrolled in this trial:
  • Patients voluntarily joined the study, signed informed consent, good compliance and follow-up.
  • unresectable locally advanced, unresectable recurrent or metastatic ESCC confirmed by histopathology (excluding mixed adenosquamous cell carcinoma …
  • Patients who have not received previous systemic treatment, or have received previous (new) adjuvant treatment / radical treatment regimen (includi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →